Knight Therapeutics Inc. (TSX:GUD)

Canada flag Canada · Delayed Price · Currency is CAD
6.17
+0.08 (1.31%)
Aug 1, 2025, 4:00 PM EDT
1.31%
Market Cap606.89M
Revenue (ttm)372.78M
Net Income (ttm)11.06M
Shares Out99.65M
EPS (ttm)0.10
PE Ratio60.96
Forward PE84.58
Dividendn/a
Ex-Dividend Daten/a
Volume40,496
Average Volume42,164
Open6.08
Previous Close6.09
Day's Range6.08 - 6.18
52-Week Range5.09 - 6.45
Beta0.15
RSI57.88
Earnings DateAug 7, 2025

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ... [Read more]

Sector Healthcare
Founded 2013
Employees 745
Stock Exchange Toronto Stock Exchange
Ticker Symbol GUD
Full Company Profile

Financial Performance

Financial Statements

News

Notice of Knight Therapeutics’ Second Quarter 2025 Results Conference Call

MONTREAL, Aug. 01, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2025 financial resu...

19 hours ago - Financial Post

Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call

MONTREAL, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2025 financial res...

19 hours ago - GlobeNewsWire

Knight Therapeutics Announces Closing of Previously Announced Acquisition of Paladin

MONTREAL, June 17, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has completed the acquisiti...

6 weeks ago - GlobeNewsWire

Knight Closes US$50 Million Revolving Credit Facility with NBC

MONTREAL, June 17, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has entere...

6 weeks ago - GlobeNewsWire

Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo's Canadian Portfolio

MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America...

2 months ago - GlobeNewsWire

Knight Therapeutics reports Q1 results

3 months ago - Seeking Alpha

Knight Therapeutics Reports First Quarter 2025 Results

MONTREAL, May 08, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results fo...

3 months ago - GlobeNewsWire

Knight Therapeutics Inc. announces voting results from the Annual General Meeting

MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a pan-American (ex-US) specialty pharmaceutical company, announced today the voting result...

3 months ago - GlobeNewsWire

Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico

MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that has assumed full commercial ac...

3 months ago - GlobeNewsWire

Notice of Knight Therapeutics’ First Quarter 2025 Results Conference Call

MONTREAL, May 01, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2025 financial result...

3 months ago - Financial Post

Notice of Knight Therapeutics' First Quarter 2025 Results Conference Call

MONTREAL, May 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2025 financial resul...

3 months ago - GlobeNewsWire

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi ® (tafasit...

4 months ago - Benzinga

Knight Therapeutics reports results

4 months ago - Seeking Alpha

Knight Therapeutics Reports Fourth Quarter and Year-End 2024 Results

MONTREAL, March 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results ...

4 months ago - GlobeNewsWire

Notice of Knight Therapeutics’ Fourth Quarter and Year End 2024 Results Conference Call

MONTREAL, March 13, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2024 ...

5 months ago - Financial Post

Notice of Knight Therapeutics' Fourth Quarter and Year End 2024 Results Conference Call

MONTREAL, March 13, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2024...

5 months ago - GlobeNewsWire

Knight Therapeutics to acquire Paladin Pharma for $120M

Samira Sakhia, CEO of Knight Therapeutics, discusses the company's acquisition of Paladin for $120 million dollars.

5 months ago - BNN Bloomberg

Knight Therapeutics to acquire Paladin for $120M

Samira Sakhia, CEO of Knight Therapeutics, discusses the company's acquisition of Paladin for $120 million dollars.

5 months ago - BNN Bloomberg

Knight Therapeutics and Helsinn Healthcare SA Expand Relationship and Enter into Exclusive License, Distribution, and Supply Agreement for Onicit®

MONTREAL and LUGANO, Switzerland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, and Helsinn Healthcare SA ...

6 months ago - GlobeNewsWire

Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico

MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo ...

8 months ago - GlobeNewsWire

Andrey Omelchak's Past Pick: Lumine, Trisura Group and Knight Therapeutics

Andrey Omelchak, president and CIO at LionGuard Capital Management, discusses his past picks: Lumine, Trisura Group and Knight Therapeutics.

8 months ago - BNN Bloomberg

Knight Therapeutics Reports Third Quarter 2024

MONTREAL, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial r...

9 months ago - GlobeNewsWire